Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tolero-LNPs
- Development stage
- Preclinical
- Lead developer
- ISAR Bioscience
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intramuscular, Subcutaneous, Intraperitoneal, Topical, Inhalation, Intradermal
01
Overview
Tolero-LNPs is a lipid nanoparticle (LNP)-based RNA medicine delivery platform developed by ISAR Bioscience, a Bavarian research company. The platform utilizes innovative, patent-protected lipids that are designed to be biodegradable and exceptionally well-tolerated by the immune system. It is specifically engineered to deliver mRNA payloads that generate immune tolerance, making it a potential therapeutic modality for autoimmune disorders. The lead application is the treatment of Graves' disease (affecting both the thyroid and the eyes), where the platform has demonstrated the ability to modulate dendritic cell activation in patient-derived samples. As of late 2024, the technology is in the preclinical development stage, with ongoing GMP manufacturing and toxicological studies aimed at initiating clinical trials.
- Other names
- Tolero-LNPTolero-LNP platformISAR Bioscience lipid nanoparticle platform
Beyond the preview
Go deeper on Tolero-LNPs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tolero-LNPs.